Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2014

Open Access 01-12-2014 | Research article

Evaluation of coexistence of Alzheimer’s disease in idiopathic normal pressure hydrocephalus using ELISA analyses for CSF biomarkers

Authors: Tae Sung Lim, Jun Young Choi, Sun Ah Park, Young Chul Youn, Hyun Young Lee, Byung Gon Kim, In Soo Joo, Kyoon Huh, So Young Moon

Published in: BMC Neurology | Issue 1/2014

Login to get access

Abstract

Background

We investigated levels of the β-amyloid 1–42 (Aβ42), total tau protein (T-tau) and tau phosphorylated at position threonine 181 (P-tau) in cerebrospinal fluid (CSF) of idiopathic normal pressure hydrocephalus (iNPH) patients and tried to find their clinical implications in the evaluation and treatment of iNPH.

Method

Twenty-five possible iNPH patients were prospectively enrolled and their CSF was collected to analyze levels of Aβ42, T-tau and P-tau using ELISA method. Gait disturbance, urinary incontinence, and cognitive impairment were semi-quantified and detailed neuropsychological (NP) test was performed.

Result

Eight iNPH patients were classified into the lower CSF Aβ42 group and 17 patients were classified into the higher CSF Aβ42 group. There was no difference in the iNPH grading score and its improvement after LP between the two groups. The lower CSF Aβ42 group showed more deficits in attention, visuospatial function and verbal memory in the baseline NP test and less improvement in phonemic categorical naming and frontal inhibitory function after LP.

Conclusions

Our study suggested that concomitant AD in iNPH patients might contribute to lumbar puncture or shunt unresponsiveness, especially in the field of cognitive dysfunction.
Appendix
Available only for authorised users
Literature
1.
Adams RD, Fisher CM, Hakim S, Ojemann RG, Sweet WH: Symptomatic occult hydrocephalus with “Normal” cerebrospinal-fluid pressure.a treatable syndrome. N Engl J Med. 1965, 273: 117-126. 10.1056/NEJM196507152730301.CrossRefPubMed
2.
Relkin N, Marmarou A, Klinge P, Bergsneider M, Black PM: Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery. 2005, 57 (3 Suppl): S4-S16. discussion ii-vPubMed
3.
Hebb AO, Cusimano MD: Idiopathic normal pressure hydrocephalus: a systematic review of diagnosis and outcome. Neurosurgery. 2001, 49 (5): 1166-1184. discussion 1184-1166PubMed
4.
Hamilton R, Patel S, Lee EB, Jackson EM, Lopinto J, Arnold SE, Clark CM, Basil A, Shaw LM, Xie SX, Grady MS, Trojanowski JQ: Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology. Ann Neurol. 2010, 68 (4): 535-540. 10.1002/ana.22015.CrossRefPubMedPubMedCentral
5.
Silverberg GD, Mayo M, Saul T, Rubenstein E, McGuire D: Alzheimer’s disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol. 2003, 2 (8): 506-511. 10.1016/S1474-4422(03)00487-3.CrossRefPubMed
6.
Silverberg GD, Mayo M, Saul T, Fellmann J, Carvalho J, McGuire D: Continuous CSF drainage in AD: results of a double-blind, randomized, placebo-controlled study. Neurology. 2008, 71 (3): 202-209. 10.1212/01.wnl.0000316197.04157.6f.CrossRefPubMed
7.
Bech-Azeddine R, Hogh P, Juhler M, Gjerris F, Waldemar G: Idiopathic normal-pressure hydrocephalus: clinical comorbidity correlated with cerebral biopsy findings and outcome of cerebrospinal fluid shunting. J Neurol Neurosurg Psychiatry. 2007, 78 (2): 157-161. 10.1136/jnnp.2006.095117.CrossRefPubMed
8.
Golomb J, Wisoff J, Miller DC, Boksay I, Kluger A, Weiner H, Salton J, Graves W: Alzheimer’s disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response. J Neurol Neurosurg Psychiatry. 2000, 68 (6): 778-781. 10.1136/jnnp.68.6.778.CrossRefPubMedPubMedCentral
9.
Bech RA, Waldemar G, Gjerris F, Klinken L, Juhler M: Shunting effects in patients with idiopathic normal pressure hydrocephalus; correlation with cerebral and leptomeningeal biopsy findings. Acta Neurochir (Wien). 1999, 141 (6): 633-639. 10.1007/s007010050353.CrossRef
10.
Patel S, Lee EB, Xie SX, Law A, Jackson EM, Arnold SE, Clark CM, Shaw LM, Grady MS, Trojanowski JQ, Hamilton RH: Phosphorylated tau/amyloid beta 1-42 ratio in ventricular cerebrospinal fluid reflects outcome in idiopathic normal pressure hydrocephalus. Fluids Barriers CNS. 2012, 9 (1): 7-10.1186/2045-8118-9-7.CrossRefPubMedPubMedCentral
11.
Kapaki EN, Paraskevas GP, Tzerakis NG, Sfagos C, Seretis A, Kararizou E, Vassilopoulos D: Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer’s disease. Eur J Neurol. 2007, 14 (2): 168-173. 10.1111/j.1468-1331.2006.01593.x.CrossRefPubMed
12.
Tarnaris A, Toma AK, Chapman MD, Keir G, Kitchen ND, Watkins LD: Use of cerebrospinal fluid amyloid-beta and total tau protein to predict favorable surgical outcomes in patients with idiopathic normal pressure hydrocephalus. J Neurosurg. 2011, 115 (1): 145-150. 10.3171/2011.2.JNS101316.CrossRefPubMed
13.
Agren-Wilsson A, Lekman A, Sjoberg W, Rosengren L, Blennow K, Bergenheim AT, Malm J: CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus. Acta Neurol Scand. 2007, 116 (5): 333-339. 10.1111/j.1600-0404.2007.00890.x.CrossRefPubMed
14.
Leinonen V, Menon LG, Carroll RS, Dello Iacono D, Grevet J, Jaaskelainen JE, Black PM: Cerebrospinal fluid biomarkers in idiopathic normal pressure hydrocephalus. Int J Alzheimers Dis. 2011, 2011: 312526-PubMedPubMedCentral
15.
Tarnaris A, Toma AK, Chapman MD, Petzold A, Kitchen ND, Keir G, Watkins LD: The longitudinal profile of CSF markers during external lumbar drainage. J Neurol Neurosurg Psychiatry. 2009, 80 (10): 1130-1133. 10.1136/jnnp.2008.171686.CrossRefPubMed
16.
Jeppsson A, Zetterberg H, Blennow K, Wikkelso C: Idiopathic normal-pressure hydrocephalus: pathophysiology and diagnosis by CSF biomarkers. Neurology. 2013, 80 (15): 1385-1392. 10.1212/WNL.0b013e31828c2fda.CrossRefPubMed
17.
Seppala TT, Nerg O, Koivisto AM, Rummukainen J, Puli L, Zetterberg H, Pyykko OT, Helisalmi S, Alafuzoff I, Hiltunen M, Jääskeläinen JE, Rinne J, Soininen H, Leinonen V, Herukka SK: CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology. 2012, 78 (20): 1568-1575. 10.1212/WNL.0b013e3182563bd0.CrossRefPubMed
18.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984, 34 (7): 939-944. 10.1212/WNL.34.7.939.CrossRefPubMed
19.
Ahn HJ, Chin J, Park A, Lee BH, Suh MK, Seo SW, Na DL: Seoul Neuropsychological Screening Battery-dementia version (SNSB-D): a useful tool for assessing and monitoring cognitive impairments in dementia patients. J Korean Med Sci. 2010, 25 (7): 1071-1076. 10.3346/jkms.2010.25.7.1071.CrossRefPubMedPubMedCentral
20.
Larsson A, Wikkelso C, Bilting M, Stephensen H: Clinical parameters in 74 consecutive patients shunt operated for normal pressure hydrocephalus. Acta Neurol Scand. 1991, 84 (6): 475-482. 10.1111/j.1600-0404.1991.tb04998.x.CrossRefPubMed
21.
Krauss JK, Regel JP, Vach W, Jungling FD, Droste DW, Wakhloo AK: Flow void of cerebrospinal fluid in idiopathic normal pressure hydrocephalus of the elderly: can it predict outcome after shunting?. Neurosurgery. 1997, 40 (1): 67-73. discussion 73-64PubMed
22.
Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E: Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?. Mol Chem Neuropathol. 1995, 26 (3): 231-245. 10.1007/BF02815140.CrossRefPubMed
23.
Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, Andreasen N, Blennow K: Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett. 2000, 285 (1): 49-52. 10.1016/S0304-3940(00)01036-3.CrossRefPubMed
24.
Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K: Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999, 56 (6): 673-680. 10.1001/archneur.56.6.673.CrossRefPubMed
25.
Moon SY, Na DL, Seo SW, Lee JY, Ku BD, Kim SY, Park KW, Shim YS, Youn YC, Chung CS, Cheong HK, Choi SH, Cha KR, Kim JE, Jeong JH: Impact of white matter changes on activities of daily living in mild to moderate dementia. Eur Neurol. 2011, 65 (4): 223-230. 10.1159/000318161.CrossRefPubMed
26.
Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, Kuiper M, Steinling M, Wolters EC, Valk J: Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992, 55 (10): 967-972. 10.1136/jnnp.55.10.967.CrossRefPubMedPubMedCentral
27.
Kim H, Na DL: Normative data on the Korean version of the Boston Naming Test. J Clin Exp Neuropsychol. 1999, 21 (1): 127-133. 10.1076/jcen.21.1.127.942.CrossRefPubMed
28.
Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka S-K, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K: CSF Biomarkers and Incipient Alzheimer disease in patients with mild cognitive impairment. JAMA: J Am Med Assoc. 2009, 302 (4): 385-393. 10.1001/jama.2009.1064.CrossRef
29.
Wilson RK, Williams MA: The role of the neurologist in the longitudinal management of normal pressure hydrocephalus. Neurologist. 2010, 16 (4): 238-248. 10.1097/NRL.0b013e3181de4907.CrossRefPubMed
30.
Lins H, Wichart I, Bancher C, Wallesch CW, Jellinger KA, Rosler N: Immunoreactivities of amyloid beta peptide((1-42)) and total tau protein in lumbar cerebrospinal fluid of patients with normal pressure hydrocephalus. J Neural Transm. 2004, 111 (3): 273-280. 10.1007/s00702-003-0075-x.CrossRefPubMed
31.
Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE: Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008, 65 (11): 1509-1517. 10.1001/archneur.65.11.1509.CrossRefPubMedPubMedCentral
32.
Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, Blennow K: Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett. 2001, 297 (3): 187-190. 10.1016/S0304-3940(00)01697-9.CrossRefPubMed
33.
Paraskevas GP, Kapaki E, Liappas I, Theotoka I, Mamali I, Zournas C, Lykouras L: The diagnostic value of cerebrospinal fluid tau protein in dementing and nondementing neuropsychiatric disorders. J Geriatr Psychiatry Neurol. 2005, 18 (3): 163-173. 10.1177/0891988705277549.CrossRefPubMed
34.
Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H: Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology. 1999, 52 (8): 1555-1562. 10.1212/WNL.52.8.1555.CrossRefPubMed
35.
Bugalho P, Alves L, Miguel R, Ribeiro O: Profile of cognitive dysfunction and relation with gait disturbance in Normal Pressure Hydrocephalus. Clin Neurol Neurosurg. 2014, 118: 83-88.CrossRefPubMed
36.
Leinonen V, Koivisto AM, Savolainen S, Rummukainen J, Tamminen JN, Tillgren T, Vainikka S, Pyykko OT, Molsa J, Fraunberg M, Pirttilä T, Jääskeläinen JE, Soininen H, Rinne J, Alafuzoff I: Amyloid and tau proteins in cortical brain biopsy and Alzheimer’s disease. Ann Neurol. 2010, 68 (4): 446-453. 10.1002/ana.22100.CrossRefPubMed
37.
Koivisto AM, Alafuzoff I, Savolainen S, Sutela A, Rummukainen J, Kurki M, Jaaskelainen JE, Soininen H, Rinne J, Leinonen V, Kuopio NPH Registry: Poor cognitive outcome in shunt-responsive idiopathic normal pressure hydrocephalus. Neurosurgery. 2013, 72 (1): 1-8. 10.1227/NEU.0b013e31827414b3. discussion 8CrossRefPubMed
38.
Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Bürger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K: Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009, 8 (7): 619-627. 10.1016/S1474-4422(09)70139-5.CrossRefPubMed
39.
Solana E, Poca MA, Sahuquillo J, Benejam B, Junque C, Dronavalli M: Cognitive and motor improvement after retesting in normal-pressure hydrocephalus: a real change or merely a learning effect?. J Neurosurg. 2010, 112 (2): 399-409. 10.3171/2009.4.JNS081664.CrossRefPubMed
Metadata
Title
Evaluation of coexistence of Alzheimer’s disease in idiopathic normal pressure hydrocephalus using ELISA analyses for CSF biomarkers
Authors
Tae Sung Lim
Jun Young Choi
Sun Ah Park
Young Chul Youn
Hyun Young Lee
Byung Gon Kim
In Soo Joo
Kyoon Huh
So Young Moon
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2014
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/1471-2377-14-66

Other articles of this Issue 1/2014

BMC Neurology 1/2014 Go to the issue

Study protocol

The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke

Research article

Actigraphy as a diagnostic aid for REM sleep behavior disorder in Parkinson’s disease

Research article

Deterioration after corticosteroids in CIDP may be associated with pure focal demyelination pattern

Research article

Perceived facilitators and barriers to self-management in individuals with traumatic spinal cord injury: a qualitative descriptive study

Study protocol

Internet-based guided self-help for glioma patients with depressive symptoms: design of a randomized controlled trial

Research article

Responsiveness of the ten-metre walk test, Step Test and Motor Assessment Scale in inpatient care after stroke